Skip to main content
Premium Trial:

Request an Annual Quote

Bernhard Spiess

Castle Biosciences has appointed Bernhard Spiess as chief operating officer. Bernhard most recently served as vice president of product management for both clinical chemistry and infectious diseases at Beckman Coulter. He spent 23 years working at Beckman Coulter and played key leadership roles in the development and commercialization of various platforms. Earlier in his career, Bernhard worked for Sanofi Diagnostics Pasteur and Abbott Diagnostics.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.